Amarin Corp Plc (AMRN)

[dukesking]

Dan, I find this to be a strange and untimely update by the AHA. Why would the AHA feel the need to update their position solely on the treatment of triglycerides and the lowering of triglycerides only? It appears to be pro lovaza as an equal to Vascepa and almost completely neglects to mention that lowering triglycerides alone has not been proven to show cardiovascular benefit and that Lovaza hasn’t shown any study that it can lower the risk of cardiovascular events like Vascepa. Why is the AHA supporting Lovaza in an update? Why are they mentioning “ no head to head study comparing the two? Only in the last sentence or two does it mention cardiovascular RRR of ReduceIt as an after thought. Very disappointing, unnecessary and irresponsible update by AHA IMO.